Sutro Biopharma (NASDAQ:STRO) Announces Quarterly Earnings Results

Sutro Biopharma (NASDAQ:STRO) released its quarterly earnings data on Monday. The company reported ($5.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($4.66) by ($0.73), FiscalAI reports. Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%. The business had revenue of $11.65 million during the quarter, compared to analyst estimates of $9.26 million.

Sutro Biopharma Price Performance

Shares of NASDAQ STRO opened at $23.57 on Wednesday. The firm has a market cap of $200.58 million, a price-to-earnings ratio of -0.90 and a beta of 1.47. The stock’s fifty day moving average price is $18.39 and its two-hundred day moving average price is $12.68. Sutro Biopharma has a one year low of $5.23 and a one year high of $26.54.

Trending Headlines about Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: HC Wainwright upgraded STRO from “neutral” to “buy” and raised its price target to $28, signaling stronger analyst conviction that supported buying interest. HC Wainwright Upgrade
• Positive Sentiment: Wells Fargo upgraded Sutro from “equal weight” to “overweight” and lifted its target to $27 (from $8), another buy-side endorsement that likely boosted investor demand. Wells Fargo Upgrade
• Positive Sentiment: Clinical progress: Sutro reported dosing three cohorts in the Phase 1 trial of STRO‑004 (a potential best‑in‑class Tissue Factor ADC) and remains on track to report initial clinical data in mid‑2026 — a pipeline catalyst that can drive upside if data are favorable. STRO-004 Clinical Update
• Neutral Sentiment: HC Wainwright published an FY2030 EPS projection of ($4.43) — below consensus — even while issuing the buy rating and higher target; this is a mixed signal (stronger sentiment but conservative long‑term earnings view). HC Wainwright Research Note
• Neutral Sentiment: Short‑interest reports in late March show effectively zero reported short shares and negligible days‑to‑cover — the filings appear anomalous and are not providing clear bearish pressure. (Multiple filings dated March 24.)
• Negative Sentiment: Recent quarterly results (reported March 23) showed a large EPS miss — ($5.39) vs. ($4.66) expected — despite revenue beating estimates; margins and ROE remain deeply negative, underscoring operational losses that keep fundamental risk elevated. Q4/FY2025 Results

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on STRO shares. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sutro Biopharma in a research note on Wednesday, December 17th. HC Wainwright raised shares of Sutro Biopharma from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $10.00 to $28.00 in a research report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Monday, December 22nd. Wells Fargo & Company upgraded shares of Sutro Biopharma from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $8.00 to $27.00 in a research note on Tuesday. Finally, Citizens Jmp raised shares of Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 target price for the company in a report on Tuesday, January 20th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Sutro Biopharma has an average rating of “Hold” and a consensus price target of $34.33.

Institutional Investors Weigh In On Sutro Biopharma

A number of institutional investors have recently modified their holdings of STRO. Velan Capital Investment Management LP raised its stake in Sutro Biopharma by 2.0% in the 3rd quarter. Velan Capital Investment Management LP now owns 3,120,000 shares of the company’s stock worth $2,709,000 after purchasing an additional 60,000 shares in the last quarter. UBS Group AG increased its holdings in shares of Sutro Biopharma by 14.0% during the third quarter. UBS Group AG now owns 1,845,839 shares of the company’s stock worth $1,602,000 after purchasing an additional 226,955 shares during the period. AQR Capital Management LLC raised its position in shares of Sutro Biopharma by 1,052.8% in the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock valued at $859,000 after buying an additional 1,206,330 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Sutro Biopharma in the second quarter valued at approximately $492,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Sutro Biopharma in the third quarter valued at approximately $387,000. Institutional investors own 96.99% of the company’s stock.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.